

**C-glucosidic ellagitannins and galloylated glucoses as potential functional food ingredients with anti-diabetic properties: a study of  $\alpha$ -glucosidase and  $\alpha$ -amylase inhibition**

Nunzio Cardullo<sup>a</sup>, Vera Muccilli<sup>a,\*</sup>, Luana Pulvirenti<sup>a</sup>, Anaëlle Cornu<sup>b</sup>,  
Laurent Pouységu<sup>b</sup>, Denis Deffieux<sup>b</sup>, Stéphane Quideau<sup>b,c</sup>, Corrado Tringali<sup>a</sup>

<sup>a</sup> *Dipartimento di Scienze Chimiche, Università degli Studi di Catania, Viale A. Doria 6, 95125-Catania, Italy*

<sup>b</sup> *Univ. Bordeaux, Institut des Sciences Moléculaires (UMR-CNRS 5255), 351 cours de la Libération, 33405 Talence Cedex, France*

<sup>c</sup> *Institut Universitaire de France, 1 rue Descartes, 75231 Paris Cedex 05, France*

**Corresponding Author**

\*(V. M.) Mail: Dipartimento di Scienze Chimiche, Università degli Studi di Catania, V.le A. Doria 6, 95125 Catania, Italy. E-mail: [v.muccilli@unict.it](mailto:v.muccilli@unict.it). Phone: +39-095-7385041 Fax: +39-095-580138.

**Authors e-mails**

Nunzio Cardullo, [ncardullo@unict.it](mailto:ncardullo@unict.it); Anaëlle Cornu, [anaelle.cornu@u-bordeaux.fr](mailto:anaelle.cornu@u-bordeaux.fr); Denis Deffieux, [denis.deffieux@u-bordeaux.fr](mailto:denis.deffieux@u-bordeaux.fr); Laurent Pouységu, [laurent.pouysegu@u-bordeaux.fr](mailto:laurent.pouysegu@u-bordeaux.fr); Luana Pulvirenti, [luanapulvirenti@unict.it](mailto:luanapulvirenti@unict.it); Stéphane Quideau, [stephane.quideau@u-bordeaux.fr](mailto:stephane.quideau@u-bordeaux.fr); Corrado Tringali, [ctringali@unict.it](mailto:ctringali@unict.it)

## 1 Abstract

2 Diabetes mellitus is a metabolic disorder characterized by hyperglycemia, which can be  
3 counteracted by inhibition of  $\alpha$ -glucosidase and  $\alpha$ -amylase, both involved in the carbohydrate  
4 metabolism. Fourteen *C*-glucosidic ellagitannins and three galloylated glucoses were studied as  
5 potential  $\alpha$ -glucosidase and  $\alpha$ -amylase inhibitors. Most of the compounds were found to be  
6 moderate inhibitors of  $\alpha$ -amylase, but potent inhibitors of  $\alpha$ -glucosidase, showing low-micromolar  
7  $IC_{50}$  values, far lower than that of the antidiabetic drug acarbose. This selectivity can be an  
8 advantage for their possible application as functional food ingredients with anti-diabetic properties  
9 because strong  $\alpha$ -amylase inhibition generally causes undesired side effects. The best inhibitors  
10 were selected for further studies. Intrinsic fluorescence measurements confirmed their high affinity  
11 towards  $\alpha$ -glucosidase, highlighting a static quenching mechanism. Circular dichroism  
12 measurements and kinetics of inhibition indicated that the most active *C*-glucosidic ellagitannin  
13 roburin D (**RobD**) is a competitive inhibitor, whereas  $\alpha$ -pentagalloylglucose ( **$\alpha$ -PGG**) acts as a  
14 mixed-type inhibitor.

15

16

17

18

19

20

21

- 22 **Keywords:** Hydrolyzable tannins, hypoglycemic activity,  $\alpha$ -glucosidase inhibition,  $\alpha$ -amylase
- 23 inhibition, intrinsic fluorescence, inhibition kinetics

## 24 1. Introduction

25 Diabetes mellitus (DM) is a rapidly growing metabolic disorder characterized by insulin hormone  
26 dysfunction, and as a result, by high blood glucose levels. Type 2 diabetes (non-insulin-dependent),  
27 most frequent in adults, accounts for around 90% of all cases of diabetes. The glycemic control is  
28 crucial in patients with DM disease; postprandial hyperglycemia may increase the risk of type 2  
29 diabetes and subsequent complications, such as cardiovascular disease, nephropathy, neuropathy,  
30 angiopathy and others (Zheng, Ley, & Hu, 2018). Furthermore, hyperglycemia increases the  
31 production of reactive oxygen species, causing oxidative tissue damage (Fiorentino, Prioletta, Zuo,  
32 & Folli, 2013). One of the strategies to manage the resulting hyperglycemia is the inhibition of  
33 carbohydrate hydrolyzing enzymes, such as  $\alpha$ -amylase and  $\alpha$ -glucosidase, both involved in the  
34 breakdown of dietary carbohydrates (Hakamata, Kurihara, Okuda, Nishio, & Oku, 2009). Acarbose,  
35 miglitol and voglibose are currently employed antidiabetic drugs based on carbohydrate structure,  
36 able to inhibit both  $\alpha$ -amylase and  $\alpha$ -glucosidase, thus reducing carbohydrate hydrolysis and  
37 consequently glucose absorption. Nevertheless, some undesired side effects, such as flatulence,  
38 diarrhea, abdominal and liver disorders, have been reported for acarbose (Godbout & Chiasson,  
39 2007) and similar drugs. Thus, the search for new  $\alpha$ -glucosidase and/or  $\alpha$ -amylase inhibitors with  
40 minor or absent undesired effects is of great importance for DM management. In recent years,  
41 natural products were found to be a promising source of  $\alpha$ -glucosidase and/or  $\alpha$ -amylase inhibitors  
42 (Brown, Anderson, Racicot, Pilkenton, & Apostolidis, 2017), thus inspiring the synthesis of new  
43 potential antidiabetic agents. Among natural products, some polyphenols occurring in edible plants  
44 show  $\alpha$ -glucosidase inhibitory activity are attractive as hypoglycemic agents in consideration of  
45 their antioxidant properties, which are able to reduce the oxidative damage associated with diabetes  
46 complications (Fiorentino et al., 2013). In this framework, some natural product analogues, namely  
47 stilbenoid glycosides (Cardullo, Spatafora, Musso, Barresi, Condorelli, & Tringali, 2015), bisphenol  
48 neolignans (Pulvirenti, Muccilli, Cardullo, Spatafora, & Tringali, 2017), and rosmarinic acid amides

49 (Cardullo et al., 2019) were also evaluated as  $\alpha$ -glucosidase inhibitors. Among plant polyphenols  
50 with antidiabetic properties, tannins raise considerable interest. This group of natural products  
51 includes structurally complex plant phenolics that can reach high molecular masses, widely  
52 distributed in higher plants, and found in almost all plant foods and beverages. Tannins have  
53 attracted scientific interest for their promising biological properties, including antioxidant,  
54 antimicrobial, antitumor and antidiabetic activity (Ajebli & Eddouks, 2019; Goncalves, Mateus, &  
55 de Freitas, 2011; Serrano, Puupponen-Pimia, Dauer, Aura, & Saura-Calixto, 2009). Considering  
56 their structural features, tannins can be classified into three major groups: 1) condensed tannins, 2)  
57 hydrolyzable tannins (mainly ellagitannins and gallotannins), and 3) phlorotannins (Quideau,  
58 Deffieux, Douat-Casassus, & Pouysegu, 2011). In recent years, the  $\alpha$ -glucosidase and/or  $\alpha$ -amylase  
59 inhibitory activity of ellagi- and gallotannins isolated from different sources have been reported  
60 (Ma et al., 2015; Serrano et al., 2009). In this context, commercial tannin mixtures employed in  
61 oenology have been recently examined, obtaining fractions enriched in hydrolyzable tannins with  
62 high antioxidative capacity and/or  $\alpha$ -glucosidase inhibitory activity (Cardullo, Muccilli, Saletti,  
63 Giovando, & Tringali, 2018; Muccilli, Cardullo, Spatafora, Cunsolo, & Tringali, 2017; Spinaci,  
64 Bucci, Muccilli, Cardullo, Nerozzi, & Galeati, 2019; Spinaci et al., 2018). Tannins are also reported  
65 as inhibitors of formation of advanced glycation end-products that contribute to the development  
66 and progression of diabetes (Khangholi, Majid, Berwary, Ahmad & Aziz, 2016). All of these  
67 findings highlight that tannins found in food and beverages may have a relevant role in the  
68 prevention or treatment of DM pathologies, mostly considering their low or absent toxicity. They  
69 could also be exploited as components of functional food ingredients with antidiabetic properties.  
70 Nevertheless, the difficulty in obtaining tannin samples with satisfactory purity causes a scarcity of  
71 systematic studies on the inhibitory properties of individual tannins towards enzymes involved in  
72 glucose absorption. Moreover, the search of potential antidiabetic agents from natural sources is  
73 frequently limited to the evaluation of  $\alpha$ -glucosidase inhibitory activity, since this enzyme

74 inhibition is part of an established protocol for diabetes therapy and corresponds to the assay most  
75 frequently employed in the preliminary steps of the search for new antidiabetic drugs. Thus, the  
76 present study is aimed at improving the understanding on the antidiabetic properties of pure C-  
77 glucosidic ellagitannins and galloylated glucoses through a study of *in vitro* inhibitory effect both  
78 on  $\alpha$ -glucosidase and  $\alpha$ -amylase by using a combination of UV-Vis absorption, fluorescence,  
79 circular dichroism and enzyme kinetic analysis.

80

## 81 **2. Materials and methods**

### 82 *2.1. Samples and chemicals*

83 Fourteen C-glucosidic ellagitannins, namely castalagin (**CSG**), vescalagin (**VSG**), castalin  
84 (**CSN**), vescalin (**VSN**), vescalene (**VSE**), roburins A-E (**RobA-RobE**), grandinin (**GRA**),  
85 acutissimin A (**AcuA**), acutissimin B (**AcuB**), epiacutissimin B (**EAcuB**), and three galloylated  
86 glucoses, namely  $\beta$ -glucogallin ( **$\beta$ -GGa**),  $\beta$ -pentagalloylglucose ( **$\beta$ -PGG**),  $\alpha$ -pentagalloylglucose  
87 ( **$\alpha$ -PGG**), were either extracted and purified from natural sources or generated by chemical  
88 (hemi)synthesis. **CSG**, **VSG**, **RobA-RobE** and **GRA** were extracted and purified from oak  
89 heartwood according to previously described protocols (Quideau et al., 2004; Vilhelmova-Ilieva,  
90 Jacquet, Quideau, & Galabov, 2014). **CSN**, **VSN** and **VSE** were generated through acidic  
91 hydrolytic treatments of **CSG** and **VSN** (Quideau et al., 2005). **AcuA**, **AcuB** and **EAcuB** were  
92 produced by hemisynthesis from **VSG** and either catechin or epicatechin as previously described  
93 (Quideau et al., 2005; Quideau, Jourdes, Saucier, Glories, Pardon, & Baudry, 2003).  **$\beta$ -GGa**,  **$\beta$ -**  
94 **PGG** and  **$\alpha$ -PGG** were produced by total synthesis according to previously described protocols  
95 (Sylla, Pouysegou, Da Costa, Deffieux, Monti, & Quideau, 2015). The purity of each compound was  
96 assessed by HPLC-UV; detailed data are reported in Supplementary material (Table S1). Quercetin,  
97  $\alpha$ -glucosidase from *Saccharomyces cerevisiae* (EC 3.2.1.20, Type I, lyophilized powder,  $\geq 10$   
98 units/mg protein;  $\alpha$ -GLU), porcine pancreas  $\alpha$ -amylase (EC 3.2.1.1, Type VI-B,  $> 5$  units/mg solid;

99  $\alpha$ -AMY), *p*-nitrophenyl- $\alpha$ -D-glucopyranoside (*p*-NP- $\alpha$ -Glc), starch from potato, 3,5-dinitrosalicylic  
100 acid (DNS), sodium potassium tartrate tetrahydrate, acarbose, NaH<sub>2</sub>PO<sub>4</sub>, Na<sub>2</sub>HPO<sub>4</sub> 7 H<sub>2</sub>O were  
101 purchased from Sigma Aldrich. All the chemicals were of analytical purity or higher and distilled  
102 water freshly filtered on 0.22  $\mu$ m was employed in the experiments.

### 103 2.2. Measurements of $\alpha$ -glucosidase inhibition

104 The  $\alpha$ -glucosidase inhibition assay was performed using the conditions previously reported  
105 (Nunzio Cardullo et al., 2019). Briefly, in a 96-well microplate, the  $\alpha$ -glucosidase solution (0.25  
106 U/ml in 50 mM phosphate buffer, pH 6.8; 100  $\mu$ l) was mixed with different aliquots (2, 4, 6, 8, 10,  
107 15  $\mu$ l) of tested compounds (stock solutions in methanol ranging from 1.2 mM to 0.6 mM). Then,  
108 the substrate *p*NP- $\alpha$ -G (78  $\mu$ M; 100  $\mu$ l) was added and the microplate was incubated at 37 °C for  
109 30 min under shaking. The reaction was stopped by adding 1 M Na<sub>2</sub>CO<sub>3</sub> solution (10  $\mu$ l) and the  
110 absorbance of *p*NP- $\alpha$ -G was measured at 405 nm with the Synergy H1 microplate reader (BioTek,  
111 Bad Friedrichshall, Germany). Acarbose and quercetin were used as reference standards. The  
112 assays were performed in triplicate with five different concentrations for each compound. The  
113 amount of methanol used in the experiment did not affect the glucosidase inhibitory activity. The  
114 inhibition percentage was calculated by the following equation:

$$115 \quad \text{inhibition \%} = \frac{(A_{\text{control}} - A_{\text{sample}})}{A_{\text{control}}} * 100 \quad (1)$$

116 where  $A_{\text{control}}$  is the absorbance measured for the mixture enzyme/substrate (without tested  
117 compounds);  $A_{\text{sample}}$  is the absorbance measured in the same conditions and in the presence of the  
118 tested compounds. The concentration required to inhibit 50% activity of the enzyme (IC<sub>50</sub>) was  
119 calculated by regression analysis.

### 120 2.4. Measurements of $\alpha$ -amylase inhibition

121 The inhibition assay with the  $\alpha$ -amylase was performed with slight modifications of a  
122 previously reported method (Ali, Houghton, & Soumyanath, 2006). A stock solution of starch

123 (0.5%) was prepared in 20 mM phosphate buffer (pH 6.9) containing 6.7 mM NaCl, the mixture  
124 was stirred at 90 °C for 20 min before use. In a typical experiment, the enzyme solution (6 U/ml in  
125 20 mM phosphate buffer containing 6.7 mM NaCl; 300 µl) was incubated at 37 °C for 10 min with  
126 different aliquots (10, 20, 40, 60, 100 µl) of the tested compounds (stock solutions were prepared in  
127 water or methanol ranging from 1.2 mM to 0.6 mM). Then, the starch solution (300 µl) was added  
128 in the test tubes and the mixtures were incubated at 37 °C for 15 min. The reaction was terminated  
129 by the addition of 600 µl of colour reagent solution (96mM DNS with 30% sodium potassium  
130 tartrate in 2N NaOH) and the mixtures were heated at 100 °C for 10 min. Each mixture was diluted  
131 with water (2 ml) and the absorbance was measured at 540 nm with a Jasco V 750 UV-Vis  
132 spectrophotometer (Milan, Italy). For each compound, the assay was performed in triplicate at five  
133 different concentrations, acarbose was used as a positive reference. The control, representing 100%  
134 enzyme activity, was carried out in the same fashion as for the other experiments, replacing the  
135 aliquots of the tested compounds with buffer. The inhibition percentage was calculated by the  
136 following equation:

$$137 \quad inhibition \% = \frac{(A_{control} - A_{sample})}{A_{control}} * 100 \quad (2)$$

138 The concentration required to inhibit 50% activity of the enzyme (IC<sub>50</sub>) was calculated by  
139 regression analysis.

#### 140 2.5. Fluorescence spectra measurements

141 The fluorescence spectra of  $\alpha$ -glucosidase and  $\alpha$ -amylase were recorded on an Agilent Cary Eclipse  
142 fluorescence spectrophotometer (Milan, Italy) in the range 300-450 nm, setting the excitation  
143 wavelength at 295 nm. Both the slits of excitation and emission were 10 nm. For each tested  
144 compound, the experiments (each in triplicate) were performed at 25, 30 and 37 °C; quercetin was  
145 employed as a reference compound. The tested compounds did not show fluorescence when  
146 irradiated at 295 nm. The concentration of starting solutions of the C-glucosidic ellagitannins and



147 galloylated glucoses were chosen on the basis of the  $IC_{50}$  values. In a typical experiment, the  $\alpha$ -  
 148 glucosidase (0.5  $\mu$ M in 0.1 M phosphate buffer containing 0.1 M NaCl, pH 6.8; 2 ml) or the  $\alpha$ -  
 149 amylase (8.0  $\mu$ M; 2 ml) was titrated by successive additions of 5 or 10  $\mu$ l of the tested compounds  
 150 as follows: for **RobB** and **RobD** from 0 to  $2.0 \times 10^{-6}$  mol  $l^{-1}$  (curves a  $\rightarrow$  q, Fig. 2A and 2B), for  $\alpha$ -  
 151 **PGG** from 0 to  $3.6 \times 10^{-6}$  mol  $l^{-1}$  (curves a  $\rightarrow$  z, Fig. 2C), for **RobB** and **RobC** from 0 to  $11.0 \times 10^{-6}$   
 152 mol  $l^{-1}$  (curves a  $\rightarrow$  h, Fig. 2D and 2E). The fluorescence spectrum was acquired 5 min after each  
 153 addition. The fluorescence measurements were elaborated according to the Stern–Volmer equation  
 154 (Peng, Zhang, Liao, & Gong, 2016):

$$155 \quad \frac{F_0}{F} = 1 + K_{sv}[Q] = 1 + K_q \tau_0 [Q] \quad (3)$$

156 and equation (4) to have information on static quenching.

$$157 \quad \log \frac{F_0 - F}{F} = \log K_a + n \log [Q] \quad (4)$$

158  $F_0$  and  $F$  are the fluorescence intensities of enzyme before and after the addition of quencher,  
 159 respectively;  $[Q]$  represents the concentration of quencher (quercetin,  $\alpha$ -**PGG**, **RobB**, **RobC**,  
 160 **RobD**);  $\tau_0$  is the average life of the fluorophore without quencher, generally valued about  $10^{-8}$  s  
 161 (Lakowicz, 2006);  $K_{sv}$  and  $K_q$  represent the quenching constant and the quenching rate constant,  
 162 respectively,  $K_a$  the binding constant and  $n$  the number of binding sites.

## 163 2.6. CD spectra measurements

164 CD spectra were recorded on a Jasco J715 spectropolarimeter (Milan, Italy) equipped with a Peltier  
 165 temperature controller set at 37 °C, and using a 1.0 mm path length quartz cuvette. CD  
 166 measurements were performed in the range 190-250 nm, in the presence or absence of the tested  
 167 compounds. Briefly, in each experiment, the  $\alpha$ -glucosidase (1  $\mu$ M in 100 mM phosphate buffer, pH  
 168 6.8; 250  $\mu$ l) was titrated with aliquots (1 or 2  $\mu$ l) of **RobD** (0.27 mM) or  $\alpha$ -**PGG** (0.35 mM), thus  
 169 the concentration of tested compounds was increased from 0:1 to 4:1 for **RobD** and from 0:1 to 6:1  
 170 for  $\alpha$ -**PGG**. The spectra were collected after each addition and corrected by subtraction of the blank  
 171 (100 mM phosphate buffer). CD spectra of **RobD** and  $\alpha$ -**PGG**, at the highest concentration tested,

172 were acquired under the same conditions. The changes of secondary structures of  $\alpha$ -glucosidase  
 173 were estimated with the DichroWeb program (Whitmore & Wallace, 2004, 2008).

#### 174 2.6. Kinetics of $\alpha$ -glucosidase inhibition

175 The modes of inhibition of  $\alpha$ -glucosidase by **RobB**, **RobD** and  **$\alpha$ -PGG** were determined by  
 176 Lineweaver-Burk plots. The experiments to determine the Michaelis-Menten constant ( $K_m$ ) and the  
 177 maximal velocity ( $v_{max}$ ) were carried out in 96-well microplates (final volume 200  $\mu$ l), employing a  
 178 fixed concentration of the enzyme (3.3 mM; 5  $\mu$ l) and increasing concentrations of *p*NP- $\alpha$ -G (0.15,  
 179 0.33, 0.50, 0.80, 1.00, 1.25, 1.50, and 2.00 mM in 50 mM phosphate buffer, pH 6.8) in the absence  
 180 or presence of the inhibitors. The experiments were carried out in triplicate. The mixtures were  
 181 incubated at 37 °C and the optical density was read at 405 nm every 1 min for 30 min with the  
 182 Synergy H1 microplate reader. Optimal amounts of the tested compounds were chosen on the basis  
 183 of the IC<sub>50</sub> values.

184 The inhibition constants were either obtained graphically from secondary plots or were calculated  
 185 from the following equations:

$$186 \quad v = \frac{v_{max}S}{K_m \left(1 + \frac{I}{K_i}\right) + S} \quad (5)$$

187 for the competitive inhibitor **RobD**;

$$188 \quad v = \frac{v_{max}S}{K_m \left(1 + \frac{I}{K_i}\right) + S \left(1 + \frac{I}{K'_i}\right)} \quad (6)$$

189 for the mixed-type inhibitor  **$\alpha$ -PGG**;

190  $v$  is the initial velocity in the absence and presence of the inhibitor,  $S$  and  $I$  are the concentration of  
 191 substrate and inhibitor, respectively;  $v_{max}$  is the maximum velocity,  $K_m$  is the Michaelis-Menten  
 192 constant,  $K_i$  is the competitive inhibition constant, and  $K'_i$  is the uncompetitive inhibition constant.

193 The replot of slope and Y-intercept of reciprocal plots *versus* the inhibitor concentration gave a  
 194 straight line, corresponding to  $K_i$  and  $K'_i$  values, respectively (Meiering et al., 2005).

195 All the data obtained were compared using Analysis of Variance (ANOVA). P values < 0.05 were  
196 considered statistically significant.


197

### 198 **3. Results and discussion**

#### 199 *3.1. $\alpha$ -Glucosidase and $\alpha$ -amylase inhibitory activity assay.*

200 As mentioned in the Introduction, in many studies carried out searching for antidiabetic agents with  
201 negligible side effects, hydrolyzable tannins from different natural sources were identified as  $\alpha$ -  
202 glucosidase and/or  $\alpha$ -amylase inhibitors. However, these reported data seldom referred to purified  
203 tannins and the study of enzyme interaction or inhibition mechanism is rarely carried out. Thus, in  
204 this work, fourteen ellagitannins (**CSG**, **VSG**, **CSN**, **VSN**, **VSE**, **RobA-E**, **GRA**, **AcuA**, **AcuB**,  
205 **EAcuB**) and three galloylated glucoses ( **$\beta$ -GGa**,  **$\beta$ -PGG**,  **$\alpha$ -PGG**) listed in Material and Methods,  
206 the structures of which are displayed in Fig. 1, were examined for  $\alpha$ -glucosidase and  $\alpha$ -amylase  
207 inhibition.

208



209

210 **Fig.1.** Chemical structures of the C-glucosidic ellagitannins and galloylated glucoses tested herein. NB: the representation of the atropisomerism of  
 211 the nonahydroxytriphenoyl (NHTP) units of the ellagitannins is depicted throughout this Figure according to the structural revision recently reported  
 212 by Matsuo and co-workers for vescalagin (**VSG**) and castalagin (**CSG**) (Matsuo, Wakamatsu, Omar, & Tanaka, 2015; Richieu, Peixoto, Pouysegu,  
 213 Deffieux, & Quideau, 2017).

214 All of these C-glucosidic ellagitannins and galloylated glucoses were subjected to *in vitro*  
 215 enzymatic activity assays towards yeast  $\alpha$ -glucosidase ( $\alpha$ -GLU) and porcine pancreatic  $\alpha$ -amylase  
 216 ( $\alpha$ -AMY), employing previously reported spectrophotometric methods (Ali et al., 2006; Cardullo et  
 217 al., 2018). The inhibitory activity data for both  $\alpha$ -GLU and  $\alpha$ -AMY are reported in Table 1 as the  
 218 concentration inhibiting 50% of the enzyme activity ( $IC_{50}$ ,  $\mu$ M); the antidiabetic drug acarbose and  
 219 the natural flavonoid quercetin were used in the assays as reference standards.

220

221 **Table 1**  
 222  $\alpha$ -Glucosidase ( $\alpha$ -GLU) and  $\alpha$ -amylase ( $\alpha$ -AMY)  
 223 inhibition activity of ellagitannins and galloylated  
 224 glucoses.

Acronym <sup>a</sup>	$IC_{50} \pm SD$ ( $\mu$ M)	
	$\alpha$ -GLU	$\alpha$ -AMY
<b>AcuA</b>	5.7 $\pm$ 1.6	101.9 $\pm$ 18.7
<b>AcuB</b>	5.0 $\pm$ 1.5	166.5 $\pm$ 16.7
<b>EAcuB</b>	5.8 $\pm$ 1.0	248.0 $\pm$ 23.7
<b>GRA</b>	8.9 $\pm$ 1.8	412.3 $\pm$ 23.7
<b>RobA</b>	5.4 $\pm$ 0.9	36.2 $\pm$ 4.1
<b>RobB</b>	3.5 $\pm$ 0.2	15.6 $\pm$ 2.0
<b>RobC</b>	10.9 $\pm$ 1.6	8.7 $\pm$ 0.9
<b>RobD</b>	2.6 $\pm$ 0.2	88.5 $\pm$ 9.1
<b>RobE</b>	7.4 $\pm$ 2.1	97.9 $\pm$ 6.4
<b>VSN</b>	n. i. <sup>b</sup>	n. i. <sup>b</sup>
<b>CSN</b>	n. i. <sup>b</sup>	n. i. <sup>b</sup>
<b>VSE</b>	14.4 $\pm$ 0.8	84.7 $\pm$ 7.2
<b>VSG</b>	7.2 $\pm$ 2.3	89.7 $\pm$ 9.3
<b>CSG</b>	7.3 $\pm$ 1.6	100.9 $\pm$ 11.2
<b><math>\beta</math>-GGa</b>	n. i. <sup>b</sup>	n. i. <sup>b</sup>
<b><math>\alpha</math>-PGG</b>	1.2 $\pm$ 0.3	32.9 $\pm$ 1.8
<b><math>\beta</math>-PGG</b>	1.4 $\pm$ 0.2	17.2 $\pm$ 1.6
<b>Que</b>	16.4 $\pm$ 1.3	33.7 $\pm$ 1.6
<b>Aca</b>	260.5 $\pm$ 15.2	50.2 $\pm$ 4.2

225 <sup>a</sup> A list of the compound names with their  
 226 acronyms is given in Materials and Methods  
 227 (Table S1)

228 <sup>b</sup> No inhibition observed up to 500  $\mu$ M

229

230 The large majority of the tested compounds strongly inhibited  $\alpha$ -GLU with  $IC_{50}$  values in the  
231 approximate range 1 – 10  $\mu$ M, lower than that of quercetin (16.4  $\mu$ M), and proved to be far more  
232 potent than acarbose (260.5  $\mu$ M). The observed inhibition of  $\alpha$ -AMY is generally weaker, with only  
233 four compounds showing  $IC_{50}$  in the range 8.7 – 32.9  $\mu$ M, all four being more active than quercetin  
234 (33.7  $\mu$ M) and acarbose (50.2  $\mu$ M). This is paradoxically a positive result, because a strong  
235 inhibition of  $\alpha$ -AMY is generally associated with undesired side effects, and a correct therapeutic  
236 approach should be based on a potent  $\alpha$ -GLU inhibition associated with a moderate  $\alpha$ -AMY  
237 inhibition (Costamagna et al., 2016; Ranilla, Kwon, Apostolidis, & Shetty, 2010). Only three  
238 compounds, namely **VSN**, **CSN**, and  **$\beta$ -GGa** showed no inhibition towards both enzymes up to 500  
239  $\mu$ M. Interestingly, these compounds have both lower molecular masses and a fewer number of  
240 phenolic groups than all of the other compounds examined, except the olefinic **VSE**, closely related  
241 to the benzylic alcohols **VSN** and **CSN**; this suggests that a more complex polyphenolic structure  
242 would be associated with stronger inhibition, at least towards  $\alpha$ -GLU. In particular, the effective  $\alpha$ -  
243 GLU inhibitors **VSG** and **CSG** ( $IC_{50} = 7.2, 7.3 \mu$ M, respectively) differ from the inactive **VSN** and  
244 **CSN** by the presence of a hexahydroxydiphenoyl unit at the 4-*O*- and 6-*O*-glucose positions. Apart  
245 from that, looking at the structures of the compounds evaluated in this study, no obvious structure-  
246 activity relationship can be highlighted, except that the epimeric pentagalloylglucoses  **$\alpha$ -PGG** and  
247  **$\beta$ -PGG**, showing  $IC_{50}$  values of 1.2  $\mu$ M and 1.4  $\mu$ M, are markedly more potent inhibitors of  $\alpha$ -GLU  
248 than all of the ellagitannins.  $IC_{50}$  values in the low micromolar range (2.6 – 10.9  $\mu$ M) were obtained  
249 for the complex flavano-ellagitannins **AcuA**, **AcuB**, and **EAcuB**, as well as for the dimeric *C*-  
250 glucosidic ellagitannins **RobA**, **RobB**, **RobC** and **RobD**, the latter being the most potent  
251 ellagitannin inhibiting  $\alpha$ -GLU. Comparable  $IC_{50}$  values towards  $\alpha$ -GLU were obtained for the  
252 epimeric couples **AcuB/EAcuB** (5.0/5.8  $\mu$ M), **VSG/CSG** (7.2/7.3  $\mu$ M) and **GRA/RobE** (8.9/7.4  
253  $\mu$ M), but this is not confirmed for the epimers **RobA/RobD** (5.4/2.6  $\mu$ M), and **RobB/RobC**  
254 (3.5/10.9  $\mu$ M).


255 The most effective inhibitors of  $\alpha$ -AMY are **RobC**, **RobB**,  **$\alpha$ -PGG** and  **$\beta$ -PGG** (IC<sub>50</sub> in the range  
256 8.7 – 32.9  $\mu$ M), whilst also being potent inhibitors of  $\alpha$ -GLU. The ellagitannins **AcuA**, **AcuB**,  
257 **EAcuB**, **GRA** and **CSG** are effective inhibitors of  $\alpha$ -GLU, but they are only mild inhibitors of  $\alpha$ -  
258 AMY (IC<sub>50</sub> in the range 100.9 – 412.3  $\mu$ M). Analogously, **RobD**, **RobE**, **VSE**, and **VSG**, good or  
259 very good inhibitors of  $\alpha$ -GLU, are only moderate inhibitors of  $\alpha$ -AMY (IC<sub>50</sub> in the range 84.7 –  
260 89.7  $\mu$ M). Based on these results, the ellagitannins **RobB** and **RobD**, as well as the pentagalloylated  
261 glucose  **$\alpha$ -PGG**, potent inhibitors of  $\alpha$ -GLU, were selected for a deeper evaluation of the  
262 interaction with this enzyme, based on intrinsic fluorescence measurements. Analogously, **RobB**  
263 and **RobC**, the most effective inhibitors of  $\alpha$ -AMY, were evaluated for the interaction with this  
264 enzyme. The pentagalloylated glucose  **$\beta$ -PGG**, epimer of  **$\alpha$ -PGG**, was not included in this step  
265 because its inhibitory effect on both  $\alpha$ -GLU and  $\alpha$ -AMY is well documented, and our results are in  
266 agreement with literature data (Gyemant et al., 2009; Toda, Kawabata, & Kasai, 2001).

267

### 268 3.2. Fluorescence spectra measurements

269 The interaction between the selected compounds and  $\alpha$ -GLU or  $\alpha$ -AMY was investigated by  
270 fluorescence quenching experiments. In a protein, tryptophan (Trp) is the main amino acid able to  
271 emit fluorescence. The interaction between the enzyme and the substrate modifies the  
272 microenvironment of Trp residues, thus producing a decrease in fluorescence (Li, Gao, Shan, Bian,  
273 & Zhao, 2009).

274 More specifically,  $\alpha$ -GLU displays an intrinsic fluorescence emission peak near 340 nm when  
275 excited at 295 nm; analogously,  $\alpha$ -AMY shows an emission peak at near 345 nm when excited at  
276 295 nm. In Figures 2A-C the fluorescence spectra of  $\alpha$ -GLU in presence of increasing  
277 concentrations of **RobB**, **RobD** and  **$\alpha$ -PGG**, respectively, are reported, whereas Figures 2D and 2E  
278 show the spectra of  $\alpha$ -AMY in presence of increasing concentrations of **RobB** or **RobC**.



279

280 **Fig. 2.** Fluorescence spectra of  $\alpha$ -GLU in the presence of different concentrations of: A) **RobB**, B)  
 281 **RobD**, C)  **$\alpha$ -PGG**. Fluorescence spectra of  $\alpha$ -AMY in the presence of different concentrations of :  
 282 D) **RobB**, E) **RobC**.

283

284 In all the experiments, the fluorescence intensity of both  $\alpha$ -GLU and  $\alpha$ -AMY was progressively  
 285 lowered by adding increasing amounts of the tested compounds, thus giving direct evidence of the  
 286 interaction between these molecules and the enzyme. The experiments were performed at three  
 287 different temperatures, namely at 25, 30 and 37 °C (See Figure S1 in Supplementary material for  
 288 experiments carried out at 30 and 37 °C), in order to have some information on the mechanism of  
 289 quenching. Fluorescence quenching occurs mainly through a static or dynamic mechanism: the



290 former implies the formation of a non-fluorescent complex, whereas the latter occurs through  
291 energy-transfer collisional processes causing the fluorescence quenching (Eftink & Ghiron, 1981).  
292 The static mechanism is characterized by a lowering of quenching constant values ( $K_{sv}$ ) with  
293 increasing temperatures because the non-fluorescent complex formation is progressively reduced.  
294 Furthermore, in these processes, the rate constant  $K_q$  is much higher than  $2.0 \times 10^{10} \text{ l mol}^{-1} \text{ s}^{-1}$  (Li,  
295 Zhou, Gao, Bian, & Shan, 2009). Conversely, in dynamic quenching a temperature increase causes  
296 an increasing number of collisions with the consequent raising of  $K_{sv}$  values, and  $K_q$  is lower than  
297  $2.0 \times 10^{10} \text{ l mol}^{-1} \text{ s}^{-1}$ .

298 The  $K_{sv}$  and  $K_q$  values for **RobB**, **RobC**, **RobD** and  **$\alpha$ -PGG** were achieved by linear plots of the  
299 Stern-Volmer equation (eq. 3), reporting  $F_0/F$  vs  $[Q]$ . In Table 2, the  $K_{sv}$  and  $K_q$  values obtained by  
300 plotting  $F_0/F$  vs  $[Q]$  are reported. As it is evident from these data, for all the tested compounds, the  
301  $K_{sv}$  values decrease with increasing temperature (25, 30 and 37 °C), and the resulting  $K_q$  values are  
302 three order of magnitude greater than  $2.0 \times 10^{10}$ , strongly indicating that fluorescence quenching  
303 occurs by static mechanism (Peng et al., 2016). In Table 2, we also report the  $K_{sv}$  and  $K_q$  values  
304 obtained for the interaction of quercetin (Que) with  $\alpha$ -GLU or  $\alpha$ -AMY; these data are in perfect  
305 agreement with those previously reported in analogous experiments by other authors (Li et al.,  
306 2009; Li et al., 2009).

307 Further parameters useful to study enzyme-tannin interactions, namely the binding constant ( $K_a$ )  
308 and the number of binding sites per enzyme molecule ( $n$ ) were obtained using eq. (4) and are  
309 reported in Table 2. It is evident that  $K_a$  values are inversely correlated with the temperature, in  
310 accordance with the variation of  $K_{sv}$ , and this corroborates the above assumption of a static  
311 quenching mechanism. Moreover, the  $K_a$  values determined for  $\alpha$ -GLU were in the order of  $10^5 \text{ l}$   
312  $\text{mol}^{-1}$  for **RobB** and **RobD** and even  $10^6 \text{ l mol}^{-1}$  for  **$\alpha$ -PGG**, suggesting a higher affinity between  
313 this pentagalloyglucose and  $\alpha$ -GLU, in accordance with a lower  $IC_{50}$  value (1.2  $\mu\text{M}$ ) in respect to  
314 those obtained for the ellagitannins **RobB** (3.5  $\mu\text{M}$ ) and **RobD** (2.6  $\mu\text{M}$ ). The  $K_a$  values obtained for  
315 the interaction of **RobB** and **RobC** with  $\alpha$ -AMY were respectively in the order of magnitude  $10^4$

316 and  $10^5 \text{ l mol}^{-1}$ , suggesting the strongest affinity of **RobC** with the enzyme; also these data are in  
 317 agreement with the observed  $\text{IC}_{50}$  values of roburins (Table 1). Furthermore, the number of binding  
 318 sites  $n$  was close to 1 for all the tested compounds, indicating that, in our experiments, fluorophore  
 319 and quencher can form a one-to-one complex, excluding a possible interaction by cooperativity  
 320 (Lissi, Calderon, & Campos, 2013).

321

322 **Table 2**

323 Quenching constants  $K_{SV}$ , quenching rate constants  $K_q$  and binding constants  $K_a$  of the interaction of  
 324 **RobB, RobC, RobD** and  **$\alpha$ -PGG** with the proper enzyme.

molecule	T (°C)	$K_{SV}$ ( $\times 10^5 \text{ l mol}^{-1}$ )	$K_q$ ( $\times 10^{13} \text{ l mol}^{-1}$ )	$R^2$	$K_a$ ( $\times 10^5 \text{ l mol}^{-1}$ )	$n$	$R^2$
$\alpha$ -glucosidase							
<b>Que</b>	25	$0.97 \pm 0.01$	$0.97 \pm 0.01$	0.996	$1.98 \pm 0.01$	0.99	0.994
	30	$0.92 \pm 0.01$	$0.92 \pm 0.01$	0.993	$1.55 \pm 0.03$	1.03	0.995
	37	$0.91 \pm 0.01$	$0.91 \pm 0.01$	0.996	$1.33 \pm 0.02$	1.06	0.992
<b>RobB</b>	25	$6.52 \pm 0.03$	$6.52 \pm 0.03$	0.995	$9.18 \pm 0.04$	0.87	0.997
	30	$5.78 \pm 0.02$	$5.78 \pm 0.02$	0.995	$6.48 \pm 0.07$	1.00	0.992
	37	$5.41 \pm 0.02$	$5.41 \pm 0.02$	0.998	$1.26 \pm 0.02$	1.04	0.999
<b>RobD</b>	25	$4.15 \pm 0.01$	$4.15 \pm 0.01$	0.998	$9.55 \pm 0.07$	0.91	0.998
	30	$4.00 \pm 0.03$	$4.00 \pm 0.03$	0.998	$2.34 \pm 0.05$	0.95	0.997
	37	$3.92 \pm 0.02$	$3.92 \pm 0.02$	0.997	$1.27 \pm 0.03$	1.06	0.993
<b><math>\alpha</math>-PGG</b>	25	$9.80 \pm 0.04$	$9.80 \pm 0.04$	0.995	$87.47 \pm 0.12$	1.09	0.996
	30	$9.52 \pm 0.02$	$9.52 \pm 0.02$	0.990	$50.11 \pm 0.16$	1.10	0.994
	37	$8.84 \pm 0.03$	$8.84 \pm 0.03$	0.998	$27.33 \pm 0.08$	1.12	0.996
$\alpha$ -amylase							
<b>Que</b>	25	$0.46 \pm 0.01$	$0.46 \pm 0.01$	0.999	$1.38 \pm 0.05$	0.98	0.996
	30	$0.39 \pm 0.02$	$0.39 \pm 0.02$	0.994	$1.24 \pm 0.03$	0.99	0.992
	37	$0.35 \pm 0.03$	$0.35 \pm 0.04$	0.999	$1.15 \pm 0.03$	1.08	0.997
<b>RobB</b>	25	$0.41 \pm 0.02$	$0.41 \pm 0.03$	0.994	$0.66 \pm 0.02$	0.99	0.996
	30	$0.36 \pm 0.01$	$0.36 \pm 0.02$	0.991	$0.59 \pm 0.01$	1.00	0.998
	37	$0.18 \pm 0.01$	$0.18 \pm 0.02$	0.995	$0.41 \pm 0.02$	1.10	0.999
<b>RobC</b>	25	$1.15 \pm 0.01$	$1.15 \pm 0.01$	0.998	$2.25 \pm 0.02$	0.91	0.995
	30	$1.15 \pm 0.01$	$1.15 \pm 0.01$	0.994	$2.25 \pm 0.02$	1.05	0.997
	37	$1.10 \pm 0.03$	$1.10 \pm 0.02$	0.997	$1.33 \pm 0.02$	1.08	0.998

$0.98 \pm 0.01$  $0.98 \pm 0.02$  $1.02 \pm 0.03$ 

---

325

326

327


328

329

330 *3.3. CD spectra measurements*

331 Circular dichroism (CD) spectroscopy is mostly used to provide information on the secondary  
332 structure of proteins in solution and, more specifically, in monitoring conformational changes of a  
333 given protein in the presence of a ligand (Allahdad, Varidi, Zadmard, & Saboury, 2018; Kayukawa,  
334 de Oliveira, Kaspchak, Sanchuki, Igarashi-Mafra, & Mafra, 2019). Thus, to achieve further  
335 confirmation of the interaction of selected tannins with  $\alpha$ -GLU, we carried out CD measurements of  
336 this enzyme in the absence and presence of different aliquots of **RobD** and  **$\alpha$ -PGG**, the compounds  
337 showing the higher inhibitory activity towards this enzyme. This step of the study was not extended  
338 to  $\alpha$ -AMY, considering that both C-glucosidic ellagitannins and galloylated glucoses showed lower  
339 inhibitory activity and weaker affinity for this enzyme.

340 CD Spectra of  $\alpha$ -GLU in the presence of **RobD** or  **$\alpha$ -PGG** were acquired in the range 195-250 nm  
341 and are reported respectively in Figures 3A and 3B.



342

343 **Fig.3.**344 CD spectra of  $\alpha$ -glucosidase ( $c = 1 \times 10^{-6} \text{ mol l}^{-1}$ )

345 in the presence of increasing amounts of: A)

346 **RobD**, B)  **$\alpha$ -PGG**. Dashed black line corresponds

347 to the algebraic sum of the individual spectra.

348 Insets: spectra of the  $\alpha$ -GLU (blue line) and **Rob**349 **D/  $\alpha$ -PGG** alone (black line).

350

351 The CD spectrum of  $\alpha$ -GLU shows two negative bands around 210 and 222 nm, attributable to352  $n \rightarrow \pi^*$  transition for the peptide bond of  $\alpha$ -helix structures, in agreement with previously reported353 findings (Peng et al., 2016). The CD spectra of **RobD** and  **$\alpha$ -PGG** in the absence of  $\alpha$ -GLU at the

354 highest concentration tested were acquired as well (Figure 3, insets). As shown in Figure 3, the

355 intensity of both bands observed in the spectrum of  $\alpha$ -GLU decreases by addition of increasing356 amounts of **RobD** or  **$\alpha$ -PGG**, indicating the loss of part of the  $\alpha$ -helix structures. This variation in

357 the secondary structure of the  $\alpha$ -GLU could originate from the interaction with **RobD** or  **$\alpha$ -PGG**.  
358 The CD spectra obtained by titration of the enzyme with increasing amount of ligand show a  
359 marked change in spectroscopic signals compared with the theoretical spectra of  $\alpha$ -GLU and **Rob**  
360 **D/  $\alpha$ -PGG** at the highest concentration tested (Figure 3, dashed black lines), thus suggesting that an  
361 enzyme-ligand interaction has occurred.

362 CD data were further analysed by the DichroWeb program in order to quantify changes in the  
363 secondary structure. According to these data (reported in Table S2 in Supplementary material), the  
364 interaction between the  $\alpha$ -GLU and **RobD** caused a decrease of  $\alpha$ -helix content (from 30% to 26%  
365 at the highest concentration of inhibitor tested). Analogously, the  $\alpha$ -helix content for  $\alpha$ -GLU  
366 gradually decreased with increasing amounts of  **$\alpha$ -PGG** (from 30% to 20% at the highest  
367 concentration of inhibitor tested). These findings further support the data obtained by fluorescence  
368 measurements. The decrease in  $\alpha$ -helix induced by **RobD** and  **$\alpha$ -PGG** is in agreement with the  
369 same behaviour previously observed for the interaction of other tannin-related compounds with  $\alpha$ -  
370 glucosidase (Ma et al., 2015).


371

#### 372 *3.4. Kinetics of $\alpha$ -glucosidase inhibition*

373 As a final step of this research, the kinetic of  $\alpha$ -GLU inhibition by **RobD** and  **$\alpha$ -PGG** was studied  
374 by means of UV spectroscopy and the mode of inhibition was determined by plotting the reciprocal  
375 of substrate concentration against the reciprocal of respective product formation rate, thus obtaining  
376 the Lineweaver-Burk plots. The obtained values for the kinetic parameters are listed in Table S3  
377 (Supplementary material). As shown in Figure 4A, the data lines of the Lineweaver–Burk plot  
378 obtained for **RobD** intersected the y-axis in the first quadrant, indicating that this C-glucosidic  
379 ellagitannin acts as a competitive inhibitor. Increasing concentration of **RobD** unaffected the  $V_{\max}$   
380 value ( $0.40 \mu\text{M min}^{-1}$ ), whereas it increased the  $K_m$  value (from 3.03 to 7.88  $\mu\text{M}$ ), supporting the  
381 finding that **RobD** inhibits the  $\alpha$ -GLU activity competitively. Moreover, a dissociation constant ( $K_i$ )  
382 value of 1.60  $\mu\text{M}$  for the enzyme-inhibitor complex was determined from the slope replot of

383 Lineweaver–Burk lines *versus* the concentration of **RobD**. As reported in the inset of Figure 4A, the  
384 data linearly fitted, suggesting a complete competitive inhibition and confirming that **RobD** bound  
385 to the free  $\alpha$ -GLU.

386 The data lines on the Lineweaver–Burk plot obtained for  **$\alpha$ -PGG** intersected in the second quadrant,  
387 indicating that this pentagalloylglucose acts as a mixed-type inhibitor (Figure 4B). The inhibition  
388 caused by  **$\alpha$ -PGG** modified both  $V_{\max}$  (from 0.15 to 0.08  $\mu\text{M min}^{-1}$ ) and  $K_m$  (from 0.50 to 1.62  $\mu\text{M}$ )  
389 values with increasing concentration of inhibitor (Table S3). From the Eq. (6), the dissociation  
390 constants  $K_i$ , which is related with the formation of an enzyme-inhibitor complex (EI), and  $K'_i$ ,  
391 which is related with the interaction of inhibitor with the enzyme-substrate complex (IES), were  
392 calculated. Furthermore, the replots of slope and Y-intercept *versus*  **$\alpha$ -PGG** concentration (insets in  
393 Figure 4B) were linearly fitted, suggesting for this inhibitor a complete and single inhibition site or  
394 a single class of inhibition site on the enzyme (Peng et al., 2016), in agreement with the  $n$  value  
395 obtained by fluorescence measurements. Finally, a  $K_i$  value of 0.52  $\mu\text{M}$  and a  $K'_i$  value of 2.32  $\mu\text{M}$   
396 were obtained, indicating that  **$\alpha$ -PGG** was able to bind more easily to the free  $\alpha$ -glucosidase rather  
397 than the ES complex.



398

399

400 **Fig. 4.** Lineweaver-Burk plots of  $\alpha$ -glucosidase inhibition at different concentrations of substrate  
 401 ( $p\text{NP-}\alpha\text{-G}$ ) of: A) **RobD**; B)  **$\alpha$ -PGG**. The insets depict the secondary plots of slope and Y-intercept  
 402 vs inhibitors concentration.  
 403

#### 404 4. Conclusions

405 In this work, we evaluated as inhibitors of yeast  $\alpha$ -glucosidase and porcine pancreatic  $\alpha$ -  
 406 amylase fourteen  $C$ -glucosidic ellagitannins and three galloylated glucoses. Many compounds were  
 407 potent inhibitors of  $\alpha$ -GLU, showing  $\text{IC}_{50}$  values less than  $10 \mu\text{M}$ , far lower than that of the  
 408 antidiabetic drug acarbose ( $260.5 \mu\text{M}$ ). Conversely, only four compounds significantly inhibited  $\alpha$ -

409 AMY with  $IC_{50}$  lower than those of quercetin or acarbose. Since a strong inhibition of  $\alpha$ -AMY  
410 generally causes undesired side effects, this could be an advantage for possible therapeutic  
411 applications. The ellagitannins **RobB** and **RobD**, as well as the galloylated glucose  **$\alpha$ -PGG**, the  
412 most potent  $\alpha$ -GLU inhibitors and moderate to good inhibitors of  $\alpha$ -AMY, were selected for a study  
413 of the interaction with  $\alpha$ -glucosidase, employing fluorescence quenching experiments. Analogously,  
414 **RobB** and **RobC** were evaluated for the interaction with  $\alpha$ -amylase. The fluorescence experiments  
415 confirmed a strong interaction of these tannins with  $\alpha$ -GLU; moreover,  $K_{sv}$  and  $K_q$  values were in  
416 agreement with a static quenching mechanism. A similar behaviour was observed for  $\alpha$ -AMY. More  
417 specifically, the  $K_a$  values obtained for  $\alpha$ -GLU suggested a higher affinity between  **$\alpha$ -PGG** and the  
418 enzyme with respect to **RobB** and **RobD**, in agreement with  $IC_{50}$  values. Analogously, the  $K_a$  value  
419 obtained for the interaction of **RobC** with  $\alpha$ -AMY was higher than that obtained for **RobB**. Further  
420 confirmation of the interaction with  $\alpha$ -GLU was obtained through CD spectra measurements,  
421 showing that the addition of inhibitors causes a progressive loss of  $\alpha$ -helix portions in the structure  
422 of the enzyme. As a final step, the kinetics of  $\alpha$ -GLU inhibition by **RobD** and  **$\alpha$ -PGG** was studied  
423 by means of UV spectroscopy. The results of Lineweaver-Burk plots pointed out that the  
424 ellagitannin **RobD** is a competitive inhibitor, whereas the pentagalloylglucose  **$\alpha$ -PGG** acts as a  
425 mixed-type inhibitor.

426 Overall, the data obtained in this work show that both C-glucosidic ellagitannins and certain  
427 galloylated glucopyranoses may have a relevant role in the prevention of Diabetes Mellitus and  
428 suggest a possible development of their use as functional food ingredients with antidiabetic  
429 properties.

430

#### 431 **Acknowledgements**

432 This research was supported by 'Piano della Ricerca di Ateneo 2016-2018, Linea d'intervento 2' of  
433 Università degli Studi di Catania, by MIUR ITALY PRIN 2017 (Project No. 2017A95NCJ\_003),



434 by the Ministère de l'Enseignement supérieur, de la Recherche et de l'Innovation and by the Centre  
435 National de la Recherche Scientifique (CNRS). The authors acknowledge the Bio-Nanotech  
436 Research and Innovation Tower (BRIT) for making available the Synergy H1 microplate reader and  
437 Prof. Alessandro D'Urso (University of Catania) for CD spectra acquisition.

438

439 **References**

- 440 Ajebli, M., & Eddouks, M. (2019). The Promising Role of Plant Tannins as Bioactive Antidiabetic  
441 Agents. *Current Medicinal Chemistry*, 26(25), 4852-4884
- 442 Ali, H., Houghton, P. J., & Soumyanath, A. (2006). Alpha-amylase inhibitory activity of some  
443 Malaysian plants used to treat diabetes; with particular reference to *Phyllanthus amarus*.  
444 *Journal of Ethnopharmacology*, 107(3), 449-455. <https://doi.org/10.1016/j.jep.2006.04.004>.
- 445 Allahdad, Z., Varidi, M., Zadnard, R., & Saboury, A. A. (2018). Spectroscopic and docking studies  
446 on the interaction between caseins and beta-carotene. *Food Chemistry*, 255, 187-196.  
447 <https://doi.org/10.1016/j.foodchem.2018.01.143>.
- 448 Brown, A., Anderson, D., Racicot, K., Pilkenton, S. J., & Apostolidis, E. (2017). Evaluation of  
449 Phenolic Phytochemical Enriched Commercial Plant Extracts on the In Vitro Inhibition of  
450 alpha-Glucosidase. *Frontiers in Nutrition*, 4. <https://doi.org/10.3389/fnut.2017.00056>.
- 451 Cardullo, N., Catinella, C., Floresta, G., Muccilli, V., Rosselli, S., Rescifina, A., Bruno, M., &  
452 Tringali, C. (2019). Synthesis of Rosmarinic Acid Amides as Antioxidative  
453 and Hypoglycemic Agents. *Journal of Natural Products*.  
454 <https://doi.org/10.1021/acs.jnatprod.8b01002>.
- 455 Cardullo, N., Muccilli, V., Saletti, R., Giovando, S., & Tringali, C. (2018). A mass spectrometry  
456 and <sup>1</sup>H NMR study of hypoglycemic and antioxidant principles from a *Castanea sativa*  
457 tannin employed in oenology. *Food Chemistry*, 268, 585-593.  
458 <https://doi.org/10.1016/j.foodchem.2018.06.117>.
- 459 Cardullo, N., Spatafora, C., Musso, N., Barresi, V., Condorelli, D., & Tringali, C. (2015).  
460 Resveratrol-Related Polymethoxystilbene Glycosides: Synthesis, Antiproliferative Activity,  
461 and Glycosidase Inhibition. *Journal of Natural Products*, 78, 2675-2683.
- 462 Costamagna, M. S., Zampini, I. C., Alberto, M. R., Cuello, S., Torres, S., Perez, J., Quispe, C.,  
463 Schmeda-Hirschmann, G., & Isla M I. (2016). Polyphenols rich fraction from *Geoffroea*  
464 *decorticans* fruits flour affects key enzymes involved in metabolic syndrome, oxidative  
465 stress and inflammatory process. *Food Chemistry*, 190, 392-402.  
466 <https://doi.org/10.1016/j.foodchem.2015.05.068>.
- 467 Eftink, M. R., & Ghiron, C. A. (1981). Fluorescence quenching studies with proteins. *Analytical*  
468 *Biochemistry*, 114, 199-227.
- 469 Fiorentino, T. V., Prioletta, A., Zuo, P., & Folli, F. (2013). Hyperglycemia-induced Oxidative  
470 Stress and its Role in Diabetes Mellitus Related Cardiovascular Diseases. *Current*  
471 *Pharmaceutical Design*, 19(32), 5695-5703.  
472 <https://doi.org/10.2174/1381612811319320005>.
- 473 Godbout, A., & Chiasson, J.-L. (2007). Who Should Benefit from the Use of Alpha-Glucosidase  
474 Inhibitors. *Current Diabetes Reports*, 7, 333-339.

- 475 Goncalves, R., Mateus, N., & de Freitas, V. (2011). Inhibition of alpha-amylase activity by  
476 condensed tannins. *Food Chemistry*, 125(2), 665-672.  
477 <https://doi.org/10.1016/j.foodchem.2010.09.061>.
- 478 Gyemant, G., Zajacz, A., Becsi, B., Rangunath, C., Ramasubbu, N., Erdodi, F., Batta, G., & Kandra,  
479 L. (2009). Evidence for pentagalloyl glucose binding to human salivary alpha-amylase  
480 through aromatic amino acid residues. *Biochimica Et Biophysica Acta-Proteins and*  
481 *Proteomics*, 1794(2), 291-296. <https://doi.org/10.1016/j.bbapap.2008.10.012>.
- 482 Hakamata, W., Kurihara, M., Okuda, H., Nishio, T., & Oku, T. (2009). Design and Screening  
483 Strategies for alpha-Glucosidase Inhibitors Based on Enzymological Information. *Current*  
484 *Topics in Medicinal Chemistry*, 9(1), 3-12. <https://doi.org/10.2174/156802609787354306>.
- 485 Kayukawa, C. T. M., de Oliveira, M. A. S., Kaspchak, E., Sanchuki, H. B. S., Igarashi-Mafra, L., &  
486 Mafra, M. R. (2019). Effect of tannic acid on the structure and activity of *Kluyveromyces*  
487 *lactis* beta-galactosidase. *Food Chemistry*, 275, 346-353.  
488 <https://doi.org/10.1016/j.foodchem.2018.09.107>.
- 489 Lakowicz, J. R. (2006). *Principles of Fluorescence Spectroscopy*. (3rd edition ed.). New York:  
490 Springer.
- 491 Li, Y., Gao, F., Shan, F., Bian, J., & Zhao, C. (2009). Study on the Interaction between 3 Flavonoid  
492 Compounds and alpha-Amylase by Fluorescence Spectroscopy and Enzymatic Kinetics.  
493 *Journal of Food Science*, 74(3), C199-C203. [https://doi.org/10.1111/j.1750-](https://doi.org/10.1111/j.1750-3841.2009.01080.x)  
494 [3841.2009.01080.x](https://doi.org/10.1111/j.1750-3841.2009.01080.x).
- 495 Li, Y. Q., Zhou, F. C., Gao, F., Bian, J. S., & Shan, F. (2009). Comparative Evaluation of  
496 Quercetin, Isoquercetin and Rutin as Inhibitors of a-Glucosidase. 57, 11463–11468.  
497 <https://doi.org/10.1021/jf903083h>
- 498 Lissi, E., Calderon, C., & Campos, A. (2013). Evaluation of the Number of Binding Sites in  
499 Proteins from their Intrinsic Fluorescence: Limitations and Pitfalls. *Photochemistry and*  
500 *Photobiology*, 89(6), 1413-1416. <https://doi.org/10.1111/php.12112>.
- 501 Ma, H., Wang, L., Niesen, D. B., Cai, A., Cho, B. P., Tan, W., Gu, Q., Xu, J., & Seeram, N. P.  
502 (2015). Structure activity related, mechanistic, and modeling studies of gallotannins  
503 containing a glucitol-core and alpha-glucosidase. *Rsc Advances*, 5(130), 107904-107915.  
504 <https://doi.org/10.1039/c5ra19014b>.
- 505 Matsuo, Y., Wakamatsu, H., Omar, M., & Tanaka, T. (2015). Reinvestigation of the  
506 Stereochemistry of the C-Glycosidic Ellagitannins, Vescalagin and Castalagin. *Organic*  
507 *Letters*, 17(1), 46-49. <https://doi.org/10.1021/ol503212v>.
- 508 Meiering, S., Inhoff, O., Mies, J., Vincek, A., Garcia, G., Kramer, B., Dormeyer, M., & Krauth-  
509 Siegel, R. L. (2005). Inhibitors of *Trypanosoma cruzi* trypanothione reductase revealed by  
510 virtual screening and parallel synthesis. *Journal of Medicinal Chemistry*, 48(15), 4793-4802.  
511 <https://doi.org/10.1021/jm050027z>.
- 512 Muccilli, V., Cardullo, N., Spatafora, C., Cunsolo, V., & Tringali, C. (2017).  $\alpha$ -Glucosidase  
513 inhibition and antioxidant activity of an oenological commercial tannin. Extraction,  
514 fractionation and analysis by HPLC/ESI-MS/MS and  $^1\text{H}$  NMR. *Food Chemistry*, 215, 50-  
515 60. <https://doi.org/10.1016/j.foodchem.2016.07.136>.
- 516 Peng, X., Zhang, G. W., Liao, Y. J., & Gong, D. M. (2016). Inhibitory kinetics and mechanism of  
517 kaempferol on alpha-glucosidase. *Food Chemistry*, 190, 207-215.  
518 <https://doi.org/10.1016/j.foodchem.2015.05.088>.
- 519 Pulvirenti, L., Muccilli, V., Cardullo, N., Spatafora, C., & Tringali, C. (2017). Chemoenzymatic  
520 Synthesis and alpha-Glucosidase Inhibitory Activity of Dimeric Neolignans Inspired by  
521 Magnolol. *Journal of Natural Products*, 80(5), 1648-1657.  
522 <https://doi.org/10.1021/acs.jnatprod.7b00250>.
- 523 Quideau, S., Deffieux, D., Douat-Casassus, C., & Pouysegu, L. (2011). Plant Polyphenols:  
524 Chemical Properties, Biological Activities, and Synthesis. *Angewandte Chemie*  
525 *International Edition*, 50(3), 586-621. <https://doi.org/10.1002/anie.201000044>.

- 526 Quideau, S., Jourdes, M., Lefeuvre, D., Montaudon, D., Saucier, C., Glories, Y., Pardon, P., &  
527 Pourquier, P. (2005). The chemistry of wine polyphenolic C-glycosidic ellagitannins  
528 targeting human topoisomerase II. *Chemistry-A European Journal*, *11*(22), 6503-6513.  
529 <https://doi.org/10.1002/chem.200500428>.
- 530 Quideau, S., Jourdes, M., Saucier, C., Glories, Y., Pardon, P., & Baudry, C. (2003). DNA  
531 topoisomerase inhibitor acutissimin A and other flavano-ellagitannins in red wine.  
532 *Angewandte Chemie International Edition*, *42*(48), 6012-6014.  
533 <https://doi.org/10.1002/anie.200352089>.
- 534 Quideau, S., Varadinova, T., Karagiozova, D., Jourdes, M., Pardon, P., Baudry, C., . Genova, P.,  
535 Diakov, T., & Petrova, R. (2004). Main structural and stereochemical aspects of the  
536 antiherpetic activity of nonhydroxyterphenoyl-containing C-glycosidic ellagitannins.  
537 *Chemistry & Biodiversity*, *1*(2), 247-258. <https://doi.org/10.1002/cbdv.200490021>.
- 538 Ranilla, L. G., Kwon, Y. I., Apostolidis, E., & Shetty, K. (2010). Phenolic compounds, antioxidant  
539 activity and *in vitro* inhibitory potential against key enzymes relevant for hyperglycemia and  
540 hypertension of commonly used medicinal plants, herbs and spices in Latin America.  
541 *Bioresource Technology*, *101*(12), 4676-4689.  
542 <https://doi.org/10.1016/j.biortech.2010.01.093>.
- 543 Richieu, A., Peixoto, P. A., Pouysegou, L., Deffieux, D., & Quideau, S. (2017). Bioinspired Total  
544 Synthesis of (-)-Vescalin: A Nonhydroxytriphenoylated C-Glycosidic Ellagitannin.  
545 *Angewandte Chemie International Edition*, *56*(44), 13833-13837.  
546 <https://doi.org/10.1002/anie.201707613>.
- 547 Serrano, J., Puupponen-Pimia, R., Dauer, A., Aura, A. M., & Saura-Calixto, F. (2009). Tannins:  
548 Current knowledge of food sources, intake, bioavailability and biological effects. *Molecular*  
549 *Nutrition & Food Research*, *53*, S310-S329. <https://doi.org/10.1002/mnfr.200900039>.
- 550 Spinaci, M., Bucci, D., Muccilli, V., Cardullo, N., Nerozzi, C., & Galeati, G. (2019). A polyphenol-  
551 rich extract from an oenological oak-derived tannin influences *in vitro* maturation of porcine  
552 oocytes. *Theriogenology*, *129*, 82-89. <https://doi.org/10.1016/j.theriogenology.2019.02.017>.
- 553 Spinaci, M., Muccilli, V., Bucci, D., Cardullo, N., Gadani, B., Tringali, C., Tamanini, C., & Galeati,  
554 G. (2018). Biological effects of polyphenol-rich extract and fractions from an oenological  
555 oak-derived tannin on *in vitro* swine sperm capacitation and fertilizing ability.  
556 *Theriogenology*, *108*, 284-290. <https://doi.org/10.1016/j.theriogenology.2017.12.015>.
- 557 Sylla, T., Pouysegou, L., Da Costa, G., Deffieux, D., Monti, J. P., & Quideau, S. (2015).  
558 Gallotannins and Tannic Acid: First Chemical Syntheses and *In Vitro* Inhibitory Activity on  
559 Alzheimer's Amyloid-Peptide Aggregation. *Angewandte Chemie International Edition*,  
560 *54*(28), 8217-8221. <https://doi.org/10.1002/anie.201411606>.
- 561 Toda, M., Kawabata, J., & Kasai, T. (2001). Inhibitory effects of ellagi- and gallotannins on rat  
562 intestinal alpha-glucosidase complexes. *Bioscience Biotechnology and Biochemistry*, *65*(3),  
563 542-547. <https://doi.org/10.1271/bbb.65.542>.
- 564 Vilhelmova-Ilieva, N., Jacquet, R., Quideau, S., & Galabov, A. S. (2014). Ellagitannins as  
565 synergists of ACV on the replication of ACV-resistant strains of HSV 1 and 2. *Antiviral*  
566 *Research*, *110*, 104-114. <https://doi.org/10.1016/j.antiviral.2014.07.017>.
- 567 Whitmore, L., & Wallace, B. A. (2004). DICHROWEB, an online server for protein secondary  
568 structure analyses from circular dichroism spectroscopic data. *Nucleic Acids Research*, *32*,  
569 W668-W673. <https://doi.org/10.1093/nar/gkh371>.
- 570 Whitmore, L., & Wallace, B. A. (2008). Protein secondary structure analyses from circular  
571 dichroism spectroscopy: Methods and reference databases. *Biopolymers*, *89*(5), 392-400.  
572 <https://doi.org/10.1002/bip.20853>.
- 573 Zheng, Y., Ley, S. H., & Hu, F. B. (2018). Global aetiology and epidemiology of type 2 diabetes  
574 mellitus and its complications. *Nature Reviews Endocrinology*, *14*(2), 88-98.  
575 <https://doi.org/10.1038/nrendo.2017.151>.

576

577